Ionis Pharmaceuticals (IONS)
(Real Time Quote from BATS)
$47.22 USD
-0.78 (-1.63%)
Updated Jul 15, 2024 11:30 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IONS 47.22 -0.78(-1.63%)
Will IONS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Other News for IONS
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Ionis Pharmaceuticals price target raised by $3 at Stifel, here's why
Ionis Pharmaceuticals: A Strong Buy on Regulatory Milestones and Pipeline Progress
Ionis Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for IONS